Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP), 2011
Superseded
Public Domain
-
August 11, 2011
File Language:
English
Details
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR)
-
Corporate Authors:
-
Description:In January 2011, the Food and Drug Administration lowered the approval age range for use of MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics), a quadrivalent meningococcal conjugate vaccine, to include persons aged 2 through 55 years. One other quadrivalent meningococcal conjugate vaccine, MenACWY-D(Menactra, Sanofi Pasteur), is licensed in the United States for prevention of meningococcal disease caused by serogroups A, C, Y, and W-135 among persons aged 2 through 55 years; MenACWY-D also is licensed as a 2-dose series for children aged 9 through 23 months. The Advisory Committee on Immunization Practices (ACIP) recommends that persons aged 2 through 55 years at increased risk for meningococcal disease and all adolescents aged 11 through 18 years be immunized with meningococcal conjugate vaccine. ACIP further recommended, in January 2011, that all adolescents receive a booster dose of quadrivalent meningococcal conjugate vaccine at age 16 years. This report summarizes data supporting the extended age indication for MenACWY-CRM and the interchangeability of the two licensed meningococcal conjugate vaccines.
-
Subjects:
-
Source:MMWR. Morbidity and mortality weekly report. 2011; 60(30):1018-9.
-
Series:
-
ISSN:0149-2195 (print) ; 1545-861X (digital)
-
Pubmed ID:21814165
-
Document Type:
-
Pages in Document:2 pdf pages
-
Volume:60
-
Issue:30
-
Collection(s):
-
Main Document Checksum:urn:sha-512:6ef63dbb37fcc2c7b235b2f396574bc7acf2ce98a9abb50063c9d678c28aa920254a1d32680cfe5d8ae98e9d94a2756331763a09af7b5aa190be5931a97a0cd7
-
Download URL:
-
File Type:
File Language:
English
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.